Skip Navigation LinksHome > May 2007 - Volume 26 - Issue 5 > VALGANCICLOVIR FOR CONGENITAL CMV INFECTION: A PILOT STUDY O...
Pediatric Infectious Disease Journal:
doi: 10.1097/01.inf.0000261111.90075.4d
Brief Reports

VALGANCICLOVIR FOR CONGENITAL CMV INFECTION: A PILOT STUDY ON PLASMA CONCENTRATION IN NEWBORNS AND INFANTS

Galli, Luisa MD*; Novelli, Andrea MD†; Chiappini, Elena PhD*; Gervaso, Paola MD*; Cassetta, Maria Iris BS†; Fallani, Stefania BS†; de Martino, Maurizio MD*

Collapse Box

Abstract

The pharmacokinetics of valganciclovir were studied in 8 infants ranging in age from 4 to 90 days (mean 20 days). We suggest that doses of 15 mg/kg given twice daily may be suitable for neonates and young infants.

© 2007 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.